GPX Medical AB (publ) has delivered a NEOLA system to Tyndall National Institute at University College Cork in Ireland (UCC). The contract’s commercial worth is estimated to be EUR 60,000.
FREMONT, CA: By selling its first device for effective lung monitoring of premature infants, GPX Medical has reached a significant milestone. After a few years of development at SmiLe Incubator, the company was listed on Nasdaq First North last year. GPX Medical creates non-invasive diagnostic equipment for medical issues in air-filled cavities like the lungs and sinuses.
“This is a breakthrough for the technology and for GPX Medical as a company. The company has a strong collaborative relationship with academic research, and it is precisely in the collaboration between academia and the business world when researchers and entrepreneurs meet that the magic happens,” says Hanna Sjöström, CEO, GPX Medical.
GPX Medical AB (publ) has delivered a NEOLA system to Tyndall National Institute at University College Cork in Ireland (UCC). NEOLA is a medical device that allows premature newborns’ lungs to be monitored continuously and non-invasively. The contract’s commercial worth is estimated to be EUR 60,000.In conjunction with the Irish Centre for Maternal and Child Health Research, the NEOLA technology will be utilized to perform a big study on newborn infants at the Tyndall National Institute research site at Cork University Maternity Hospital (INFANT). A total of 200 newborns will be included in the trial.
“Hanna heads GPX Medical skillfully and deliberately. We would like to congratulate her and her team on this fabulous achievement. GPX Medical is an example of a company based on outstanding research from Lund University that has been supported by the innovation system, and then effectively developed by brilliant entrepreneurs,” says Ebba Fåhraeus, CEO, SmiLe Incubator.